Tolerability of Three Local Anesthetic Formulations in Conjunction With NGX-4010 for the Treatment of Neuropathic Pain

Phase 2

Completed

• Conditions: Herpes Zoster; Diabetic Neuropathies; Neuralgia; Polyneuropathies; Pain; Diabetes Mellitus; HIV Infections; Peripheral Nervous System Diseases

• Registration Number: NCT00082316
• Lead Sponsor: NeurogesX

Brief Summary

This study is a randomized, open-label multi-center evaluation of the tolerability of treatment with NGX-4010 in conjunction with pre-patch topical application of one of three 4% lidocaine-based local anesthetic products. Eligible subjects will have moderate to severe neuropathic pain secondary to painful diabetic neuropathy (PDN), postherpetic neuralgia (PHN) or HIV-associated neuropathy (HIV-AN), with average numeric pain rating scale (NPRS) scores during screening of 3 to 8 (inclusive).

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2004-05-05
• Study First Submitted QC: 2004-05-06
• Study First Posted: 2004-05-07
• Status Verified: 2008-01
• Last Update Submitted: 2008-01-03
• Last Update Posted: 2008-01-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

NeurogesX Investigational Site; 🇺🇸 Salt Lake City, Utah, United States